According to XBiotech's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2023 the company had a P/S ratio of N/A.
Year | P/S ratio | Change |
---|---|---|
2023 | N/A | -100% |
2022 | 26.6 | 44.85% |
2021 | 18.4 | 76.73% |
2020 | 10.4 | |
2019 | N/A | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
uniQure QURE | 15.5 | N/A | ๐ณ๐ฑ Netherlands |
Calithera Biosciences
CALA | N/A | N/A | ๐บ๐ธ USA |
Enzo Biochem ENZ | 4.40 | N/A | ๐บ๐ธ USA |